ReviewBlood pressure monitoring2013
Cost-effectiveness of secondary screening modalities for hypertension.
Review in Blood pressure monitoring, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Multifaceted Implementation Strategy to Increase Out-of-Office Blood Pressure Monitoring: The EMBRACE Cluster Randomized Clinical Trial.JAMA network open · 2023Trial
- Article
- Design and study protocol for a cluster randomized trial of a multi-faceted implementation strategy to increase the uptake of the USPSTF hypertension screening recommendations: the EMBRACE study.Implementation science : IS · 2020Article
- Revisions of Medicare reimbursement policy for ambulatory blood pressure monitoring and the role of qualitative analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Prevalence of Masked Hypertension Among US Adults With Nonelevated Clinic Blood Pressure.American journal of epidemiology · 2017Article
- Blood Pressure Measurement Modalities: A Primer for Busy Practitioners.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Diagnosing hypertension: Evidence supporting the 2015 recommendations of the Canadian Hypertension Education Program.Canadian family physician Medecin de famille canadien · 2015Review
- Ambulatory blood pressure monitoring in clinical practice: a review.The American journal of medicine · 2015Review
- Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries.Journal of the American Society of Hypertension : JASH · 2014Article
- Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.Endocrine · 2014Review
- Use of ambulatory blood pressure monitoring to guide hypertensive therapy.Current treatment options in cardiovascular medicine · 2013Article
- Ambulatory blood pressure monitoring in daily practice.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundClinic-based blood pressure (CBP) has been the default approach for the diagnosis of hypertension, but patients may be misclassified because of masked hypertension (false negative) or 'white coat' hypertension (false positive). The incorporation of other diagnostic modalities, such as home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM), holds promise to improve diagnostic accuracy and subsequent treatment decisions. MATERIALS AND
methodsWe reviewed the literature on the costs and cost-effectiveness of adding HBPM and ABPM to routine blood pressure screening in adults. We excluded letters, editorials, and studies of pregnant and/or pre-eclamptic patients, children, and patients with specific conditions (e.g. diabetes).
resultsWe identified 14 original, English language studies that included cost outcomes and compared two or more modalities. ABPM was found to be cost saving for diagnostic confirmation following an elevated CBP in six studies. Three of four studies found that adding HBPM to an elevated CBP was also cost-effective.
conclusionExisting evidence supports the cost-effectiveness of incorporating HBPM or ABPM after an initial CBP-based diagnosis of hypertension. Future research should focus on their implementation in clinical practice, long-term economic values, and potential roles in identifying masked hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.